InforSense Expands Ongoing Collaboration with AstraZeneca
News Dec 15, 2005
InforSense Ltd has announced that AstraZeneca has strengthened their strategic commitment to InforSense technology across their research and development organization through a new multi-year global licensing deal.
Scientists at AstraZeneca R&D sites will use InforSense’s workflow-based integrative analytics environment, InforSense® KDE, to derive research intelligence and enhance productivity in their core drug discovery programs.
InforSense technology has been used at AstraZeneca since 2001. Following pilot installations, the global licensing agreement expands access to InforSense KDE across their R&D organization for integrative biology, chemistry and text mining applications.
The agreement also includes professional services by InforSense to enable AstraZeneca to leverage their existing discovery software investments within InforSense KDE workflows.
"InforSense is delighted to expand our ongoing collaboration with AstraZeneca," commented Joseph F. Donahue, Chief Business Officer of InforSense.
"One of the major competitive discriminators between Pharma R&D pipelines will be the speed and effectiveness by which they integrate both external and internal data, as well as software tools, within and across domains."
"InforSense technology will enable AstraZeneca to provide such integration across their entire organization to leverage their knowledge of biology and chemistry research in new ways."
"We have recognized the potential value of InforSense integrative analytics technology at AstraZeneca for effective research decision-making over recent years," said Martyn Wilkins, Director of Discovery Informatics Portfolio at AstraZeneca.
"By expanding our commitment to InforSense KDE, we will empower more scientists across our organization to effectively use information-driven analytics to inform and accelerate their research."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE